Akcea Therapeutics, a biopharmaceutical company, is focused on developing and commercializing treatments for serious and rare diseases. Its flagship products, TEGSEDI and WAYLIVRA, are already approved in various regions, and the company is also working on a pipeline of potential new drugs, including AKCEA-APO(a)-LRx, vupanorsen, AKCEA-APOCIII-LRx, and AKCEA-TTR-LRx. All of the company's medicines are based on antisense technology developed by Ionis Pharmaceuticals, which is a majority shareholder in Akcea. The company is headquartered in Boston and is working to establish a global infrastructure for the distribution of its products.
Akcea Therapeutics, Inc.'s ticker is AKCA
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 201-500 employees working at Akcea Therapeutics, Inc.
It is https://akceatx.com/
Akcea Therapeutics, Inc. is in the Healthcare sector
Akcea Therapeutics, Inc. is in the Biotechnology industry
The following five companies are Akcea Therapeutics, Inc.'s industry peers: